Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peptide Bonds02:43

Peptide Bonds

83.3K
A peptide bond covalently attaches amino acids through a dehydration reaction. One amino acid's carboxyl group and another amino acid's amino group combine, releasing a water molecule. The resulting bond is the peptide bond. The products that such linkages form are peptides. As more amino acids join this growing chain, the resulting chain is a polypeptide. Each polypeptide has a free amino group at one end. This end has the N-terminal, or the amino-terminal, and the other end has a free...
83.3K
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

1.1K
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
1.1K
Peptide Identification Using Tandem Mass Spectrometry01:33

Peptide Identification Using Tandem Mass Spectrometry

8.5K
Tandem mass spectrometry, also known as MS/MS or MS2, is an analytical technique that employs two mass analyzers. Essentially it is a series of mass spectrometers that helps isolate a particular biomolecule and then helps study its chemical properties.
This technique helps gather information regarding the protein from which the peptide was obtained and to study the peptides’ amino acid sequence. Identifying peptides from a complex mixture is an important component of the growing field of...
8.5K
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

2.4K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
2.4K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.2K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

968
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
968

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pulmonary Vein Isolation: Patient Experience under Conscious Sedation versus Anaesthesia.

Irish medical journal·2026
Same author

Where do we go from here? The personal impact of adverse events and complications in surgeons: Results from a cross-sectional study.

The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland·2025
Same author

Cardiovascular risk assessment for osteoporosis patients considering Romosozumab.

Bone·2024
Same author

Uncertainty in low back pain care - insights from an ethnographic study.

Disability and rehabilitation·2022
Same author

Comparing traditional modeling approaches versus predictive analytics methods for predicting multiple sclerosis relapse.

Multiple sclerosis and related disorders·2022
Same author

The toxic cutaneous effects of Gamma Butyrolactone (GBL).

Burns : journal of the International Society for Burn Injuries·2021

Related Experiment Video

Updated: Feb 9, 2026

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate HoLEP.
06:04

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate HoLEP.

Published on: March 6, 2018

17.6K

Angiogenic peptides in prostatic disease.

K Walsh1, R A Sherwood, T K Dew

  • 1Department of Urology, Kings College Hospital, London, UK.

BJU International
|November 26, 1999
PubMed
Summary

Serum vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) levels do not reliably distinguish benign prostatic hyperplasia from prostate cancer. However, bFGF may help differentiate local from advanced cancer.

More Related Videos

How to Study Basement Membrane Stiffness as a Biophysical Trigger in Prostate Cancer and Other Age-related Pathologies or Metabolic Diseases
13:18

How to Study Basement Membrane Stiffness as a Biophysical Trigger in Prostate Cancer and Other Age-related Pathologies or Metabolic Diseases

Published on: September 20, 2016

10.2K
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.8K

Related Experiment Videos

Last Updated: Feb 9, 2026

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate HoLEP.
06:04

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate HoLEP.

Published on: March 6, 2018

17.6K
How to Study Basement Membrane Stiffness as a Biophysical Trigger in Prostate Cancer and Other Age-related Pathologies or Metabolic Diseases
13:18

How to Study Basement Membrane Stiffness as a Biophysical Trigger in Prostate Cancer and Other Age-related Pathologies or Metabolic Diseases

Published on: September 20, 2016

10.2K
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.8K

Area of Science:

  • Oncology
  • Biochemistry

Background:

  • Angiogenesis plays a crucial role in tumor growth and metastasis.
  • Vascular Endothelial Growth Factor (VEGF) and Basic Fibroblast Growth Factor (bFGF) are key regulators of angiogenesis.
  • Identifying reliable biomarkers for prostate cancer progression is essential for effective management.

Purpose of the Study:

  • To evaluate the diagnostic and prognostic value of serum VEGF and bFGF concentrations.
  • To assess their potential as markers for malignancy and metastasis in prostate disease.
  • To compare their utility against prostate-specific antigen (PSA).

Main Methods:

  • Serum samples were collected from 106 patients with benign prostatic hyperplasia (BPH), localized prostate cancer, advanced prostate cancer, or metastatic prostate cancer.
  • Histological diagnosis and bone scan results confirmed disease status.
  • Serum levels of VEGF, bFGF, and PSA were quantified using immunoassay techniques.

Main Results:

  • Serum VEGF and bFGF levels did not significantly differ between BPH and metastatic prostate cancer groups.
  • A significant 1.6-fold difference in serum bFGF was observed between local and advanced prostate cancer (P=0.006).
  • Serum PSA levels showed greater utility in distinguishing disease states compared to VEGF and bFGF.

Conclusions:

  • Serum VEGF and bFGF are not effective biomarkers for differentiating benign from malignant prostate disease.
  • Serum bFGF may offer some value in distinguishing localized from advanced prostate cancer.
  • Serum PSA remains a more valuable marker for prostate cancer assessment than VEGF or bFGF.